
Answering the Transplant Question for Newly Diagnosed Patients - The FAS... youtu.be/4dO24XN1zUU?is=H66F… via @YouTube

Aggregating investigators, patients and private entities to develop better therapies through efficient and patient-centered clinical trials

Answering the Transplant Question for Newly Diagnosed Patients - The FAS... youtu.be/4dO24XN1zUU?is=H66F… via @YouTube

Don’t know about other but in my academic practice, I am fortunate to care for ~ 70-75 myeloma patients weekly! I love it and patient care remains my “top” priority!
It's funny seeing some academic doctors complain that today's medical students and residents are too soft. Some of these docs see like 10 patients a week and don't come near a patient without an NP buffering zone.

CoMMit publication alert! Patients with standard risk NDMM and 12-month sustained MRD negativity and NO further therapy have ~2.5% year risk of progression!! nature.com/articles/s41375-0…

This paradigm-challenging trial is 💯 accrued! Congratulations to the sites, investigators, staff and our gratitude to patients. @bhemato @ldandersonjr @nsc_natalie @SusanBal9 @CBCIDocs @rajshekharucms @huntsmanMM @RahulBanerjeeMD @DholariaMD @MMBaljevicMD @End_myeloma

IMWG recommendatons for Solitary Plasmacytoma JCO @myelomaMD @VincentRK @chngwj @End_myeloma @dra_v_hungria @JHillengass @sykristinsson @SagarLonialMD @EliasKarlMai @TomMartinMD @jmikhaelmd @NikhilMunshiMD @BrunoPaiva_UNAV @_DrCP @RascheLeo @JoshuaRichterMD @szusmani @thanosdimop

CoMMit Publication- Redefining FHR MM in the context of upfront QUAD- Ravi - 2026 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wi…

Last call! We are approaching completion of accrual for this paradigm-challenging trial! @bhemato @ldandersonjr @DholariaMD @HealthTree @RahulBanerjeeMD @ColoradoBlood @rajshekharucms @huntsmanMM @OHSUKnight @SusanBal9 @MMBaljevicMD

Together we have accrued>160 #mmsm patients to transformative CoMMit trials in 2025!! Breakthroughs are on reach, and it will need your support. Please donate commitmyelomatrials.org

I believe second milestone is clear. we must do the work to finish the journey. #mmsm @ESHaematology @CoMMitTrials

***COMMIT Publication Alert*** British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/…

**CoMMit Publication** Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy ashpublications.org/blood/ar…

In @CoMMitTrials we are testing Tec-Dara as consolidation-maintenance, fixed duration, steroid free. Hoping to prevent progression from happening in first place. @MyelomaTeacher @grpetersen1
Original Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (MajesTEC-3 phase 3 trial) nej.md/4431DUD #ASH25 | @ASH_hematology

#ASH25 not many investigator meetings look like this, but the @CoMMitTrials meeting thanks to @End_myeloma! 🍷 not shown, nor the 🛩️ Luciano has earned. Look for many innovative trial results coming soon, including MASTER-2 with MRD-guided decision-making!

Productive evening conspiring against myeloma. This fantastic group accrued >150 patients in MM treatment trials in 2025. Several key colleagues couldn't make to MCO, will join us next year.

Commit crew dissecting #ASH25 data and planing the next generation of myeloma trials. Let's keep pushing! @RahulBanerjeeMD

Happy Giving Tuesday! Get to know our group and our mission and, if you like it, consider giving your support. commitmyelomatrials.org